Table 1

Hybridizations performed in the CRH-R1 abolition experiment

Genotype (symbol)

Treatment (days)

Group ID

N

129Ola/CD1 knockout (k)

0

k0

4

129Ola/CD1 heterozygous (h)

0

h0

4

129Ola/CD1 heterozygous (h)

1

h1

5

129Ola/CD1 wild type (w)

0

w0

4

129Ola/CD1 wild type (w)

1

w1

4

129Ola/CD1 wild type (w)

7

w7

3

129SvJ wild type (s)

0

s0

4

129SvJ wild type (s)

1

s1

3

129SvJ wild type (s)

7

s7

2

Total

33

Thirty-three 12-week-old male mice with the genotypes shown in column 1 (k were CRH-R1 deficient animals, h and w were their littermates) were treated orally with an antagonist directed against the CRH-R1 (Janssen compound R121919) for 0, 1 or 7 days at a dose of 40 mg per kg body weight. Untreated groups (h0, w0, s0) were used to normalize the data and do not appear in Figures 5 and 6.

Landgrebe et al. Genome Biology 2002 3:research0019.1   doi:10.1186/gb-2002-3-4-research0019